Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences

Autor: Edine Tiemersma, Susan van den Hof, Gunta Dravniece, Fraser Wares, Yohannes Molla, Yusie Permata, Endang Lukitosari, Mamel Quelapio, Si Thu Aung, Khay Mar Aung, Hoang Thanh Thuy, Vu Dinh Hoa, Merkinai Sulaimanova, Saadat Sagyndikova, Mavluda Makhmudova, Alijon Soliev, Michael Kimerling

Publikováno v: European Respiratory Review, Vol 28, Iss 153 (2019)

New drugs and shorter treatments for drug-resistant tuberculosis (DR-TB) have become available in recent years and active pharmacovigilance (PV) is recommended by the World Health Organization (WHO) at least during the early phases of implementation,

Externí odkaz: https://doaj.org/article/b36abbdc62434a659f2154b2d500c756

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study.

Autor: Helen R Stagg, James Brown, Elmira Ibraim, Vija Riekstiņa, Piret Viiklepp, Andra Cīrule, Horia Cocei, Manfred Danilovitš, Gunta Dravniece, Charlotte Jackson, Peter J White

Publikováno v: PLoS ONE, Vol 10, Iss 11, p e0142425 (2015)

Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases. Utilising data from three different settings (Estonia, Latvia, Romania) we sought to contrast drug

Externí odkaz: https://doaj.org/article/6e7f0a930bca4524b8bd86b70da422e1

Standardised shorter regimens

Autor: Syed, Abidi, Jay, Achar, Mourtala Mohamed, Assao Neino, Didi, Bang, Andrea, Benedetti, Sarah, Brode, Jonathon R, Campbell, Esther C, Casas, Francesca, Conradie, Gunta, Dravniece, Philipp, du Cros, Dennis, Falzon, Ernesto, Jaramillo, Christopher, Kuaban, Zhiyi, Lan, Christoph, Lange, Pei Zhi, Li, Mavluda, Makhmudova, Aung Kya Jai, Maug, Dick, Menzies, Giovanni Battista, Migliori, Ann, Miller, Bakyt, Myrzaliev, Norbert, Ndjeka, Jürgen, Noeske, Nargiza, Parpieva, Alberto, Piubello, Valérie, Schwoebel, Welile, Sikhondze, Rupak, Singla, Mahamadou Bassirou, Souleymane, Arnaud, Trébucq, Armand, Van Deun, Kerri, Viney, Karin, Weyer, Betty Jingxuan, Zhang, Faiz, Ahmad Khan

Publikováno v: The European respiratory journal. 55(3)

We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a standardised regimen of 9-12 months (the "shorter regimen") and ind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8bece38bd5dfd4325bb5fea04c80f1d9
https://pubmed.ncbi.nlm.nih.gov/32198274

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

Autor: Liga Kuksa, James W. Brown, Vija Riekstiņa, Helen R. Stagg, Gunta Dravniece, Vaira Leimane, Charlotte Jackson, Peter J White, Ģirts Šķenders, Andra Cīrule

Publikováno v: Emerging Infectious Diseases
Stagg, H R, White, P J, Riekstiņa, V, Cīrule, A, Šķenders, Ģ, Leimane, V, Kuksa, L, Dravniece, G, Brown, J & Jackson, C 2016, ' Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia ', Emerging Infectious Diseases, vol. 22, no. 3, pp. 482-90 . https://doi.org/10.3201/eid2203.151227
Emerging Infectious Diseases, Vol 22, Iss 3, Pp 482-490 (2016)

This test decreased time to treatment initiation by 66%–84%.
Few studies have examined whether the Xpert MTB/RIF test improves time to treatment initiation for persons with multidrug-resistant tuberculosis (MDR TB). We determined the impact of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7dff3b50c33775e4f3ca4c545f3e91d
http://hdl.handle.net/10044/1/30798

[Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis]

Autor: Isdore Chola Shamputa, Sang Nae Cho, Kai Kliiman, Allison Taylor, E.K. Cho, Ingrida Sture, Cesar Bonilla, Carmen Suarez, Inga Norvaisha, Erika Sigman, Tatiana Khorosheva, Vija Riekstina, Julia Ershova, Elena V. Kiryanova, Tracy Dalton, Ronel Odendaal, Tatyana G. Smirnova, Michael P. Chen, Vaira Leimane, Grigory V. Volchenkov, Martie van der Walt, Tatiana Kuznetsova, Seokyong Eum, Klavdia Levina, Yung-Chao Lei, Tiina Kummik, Martin Yagui, Elena E. Larionova, Wanpen Wattanaamornkiet, Hee Jin Kim, Gloria Yale Calahuanca, Thelma E. Tupasi, Laura E. Via, Olga V. Demikhova, Tatiana Somova, Jong Seok Lee, Carmen Contreras, Jaime Bayona, Oswaldo Jave, M. Tarcela Gler, Ruwen Jou, Sofia N. Andreevskaya, Clifton E. Barry, Soo Hee Hwang, Wei-Lun Huang, Melanie Wolfgang, C. Perez, Irina A. Vasilieva, Somsak Akksilp, Rattanawadee Akksilp, Piret Viiklepp, Wanlaya Sitti, Larisa Chernousova, Charlotte Kvasnovsky, Liga Kuksa, Vladislav V. Erokhin, Kathrine R. Tan, Luis Asencios, J. Peter Cegielski, Irina Degtyareva, Seung Kyu Park, M. Therese, Ekaterina V. Kurbatova, Angela Song-En Huang, Girts Skenders, Chang Ki Kim, Anda Cirula, Manfred Danilovits, Doosoo Jeon, Lois Diem, Kristine Rose Pua, Janice Campos Caoili, Seonyeong Min, Jeanette Brand, Evgenia S. Nemtsova, Beverly Metchock, Joey Lancaster, Gunta Dravniece, Boris Y. Kazennyy, Ying Cai, Sarah Smith

Publikováno v: Medecine et maladies infectieuses. 45(1-2)

(See the Editorial Commentary by Daley and Horsburgh on pages 1064–5.) Microbial drug resistance has become a major public health concern worldwide. In the case of tuberculosis, the first global drug resistance survey, published in 1997, reported m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0daf1b59af079fb5d4a42fae67e34e51
https://pubmed.ncbi.nlm.nih.gov/25057101